Baseline data from the control arm of the STAMPEDE trial

One of the more interesting sets of data on metastatic prostate cancer to be presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago this year will be some of the very earliest data from the STAMPEDE trial, which we have discussed in some detail in an earlier post. … READ MORE …

STAMPEDE: an important trial in the management of advanced prostate cancer

Most of the time, when we talk about clinical trials of drugs (or other treatments) for prostate cancer, we are talking about trials in which new treatment X is compared to standard (current) treatment Y or, if there is no standard, new treatment Z is compared to a placebo (a benign, “dummy” substitute). … READ MORE …

Tuesday’s news update: November 18, 2008

Today’s news items include information about:

  • The potential of spinal MRI in diagnosis of men at risk for spinal metastasis
  • A review of data on use of PDE5 inhibitors to manage post-surgical erectile dysfunction
  • A “flare” phenomenom associated with docetaxel therapy in some patients
  • The current status of the STAMPEDE clinical trial … READ MORE …
Follow

Get every new post delivered to your Inbox.

Join 1,074 other followers